Revolution Medicines presents updated zoldonrasib data at AACR meeting

April 19, 2026 2:00 PM

Revolution Medicines Inc. (NASDAQ: RVMD) presented updated Phase 1 clinical data for zoldonrasib in patients with previously treated KRAS G12D ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found